

Capturing the evidence on access to essential antibiotics in refugee and migrant populations



Global Evidence Review on Health and Migration (GEHM) series

The GEHM series is an evidence-informed normative product of the WHO Health and Migration Programme to inform policy-makers on migration-related public health priorities. These reviews aim to respond to policy questions identified as priorities by summarizing the best available evidence worldwide and proposing policy considerations. By addressing data gaps on the health status of refugees and migrants, the GEHM series aims to support evidence-informed policy-making and targeted interventions that are impactful and make a difference in the lives of these populations.

Capturing the evidence on access to essential antibiotics in refugee and migrant populations

Capturing the evidence on access to essential antibiotics in refugee and migrant populations

(Global Evidence Review on Health and Migration (GEHM) series)

ISBN 978-92-4-005780-7 (electronic version))

ISBN 978-92-4-005781-4 (print version)

© **World Health Organization 2022**

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; <https://creativecommons.org/licenses/by-nc-sa/3.0/igo>).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: "This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition".

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization (<http://www.wipo.int/amc/en/mediation/rules/>).

Suggested citation. . Capturing the evidence on access to essential antibiotics in refugee and migrant populations. Geneva: World Health Organization; 2022 (Global Evidence Review on Health and Migration (GEHM) series). Licence: [CC BY-NC-SA 3.0 IGO](https://creativecommons.org/licenses/by-nc-sa/3.0/igo).

Cataloguing-in-Publication (CIP) data. CIP data are available at <http://apps.who.int/iris>.

Sales, rights and licensing. To purchase WHO publications, see <http://apps.who.int/bookorders>. To submit requests for commercial use and queries on rights and licensing, see <https://www.who.int/copyright>.

Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

General disclaimers. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

Contents

Foreword	v
Preface	viii
Acknowledgements	xi
Abbreviations and acronyms	xiii
Executive summary	xiv
1. Introduction	1
1.1 Background	1
1.2 Objective of the Report	3
1.3 Methodology	4
2. Results	6
2.1 Access to antibiotics	6
2.2 Appropriate use of antibiotics	10
2.3 Barriers to access to and appropriate use of antibiotics	14
2.4 Interventions to improve access to and use of antibiotics	22
3. Discussion	25
3.1 Implications for global governance and surveillance	25
3.2 Implications for improving antibiotic access and use at national level	26
3.3 Policy considerations	29
4. Conclusions	31
References	32
Annex 1. Search strategy	50
Annex 2. Studies identified in the literature search	56

Foreword

World Health Organization (WHO) has an ambitious agenda for universal health coverage, highlighted in its Thirteenth General Programme of Work 2019–2023 and the Triple Billion Targets, that is designed to fully support the United Nations 2030 Agenda for Sustainable Development and Sustainable Development Goals (SDGs).

Much has been achieved over the last five years. Regarding communicable diseases, the SDG target on hepatitis B has been met, and since 2015 the number of people who have received treatment for hepatitis C has increased ninefold to 9.4 million, thus reversing the trend of increasing mortality for the first time.

The world may be close to our target of 1 billion people enjoying better health and well-being by 2023, although progress is only about one quarter of what is required to reach the relevant SDG targets. Unfortunately, on universal health coverage the situation is much less satisfactory, with progress of less than one quarter of what is required to reach the Triple Billion Target. Therefore, there is still much to be done.

Despite real successes in some areas, compelling challenges remain. One is antimicrobial resistance (AMR), which is the subject of this Global Evidence Review on Health and Migration (GEHM). AMR is a complex global health, socioeconomic and development challenge, with bacterial AMR alone causing over 1.27 million deaths per year worldwide. Left unchecked, AMR has the potential to derail progress towards the Triple Billion Targets and the SDGs.

AMR occurs when bacteria, viruses, fungi and parasites change over time and no longer respond to medicines, making infections harder to treat and increasing the risk of disease spread, severe illness and death. Therefore, AMR is a complex global challenge with significant implications for human health, social well-being and economic development. Systematic misuse and overuse of antibiotics and other antimicrobials in both human medicine, veterinary medicine (terrestrial and aquatic) and food production (animals and plants) have put every nation at risk. The irrational use of antibiotics during pandemics and health emergencies also contributes to the emergence and spread of AMR. Unfortunately, the development pipeline for replacement antibiotic products is very weak. Without harmonized and immediate action on a global scale, the world may well be heading back towards a pre-antibiotic era in which common infections could once again become untreatable and lethal.

Effectively addressing AMR requires a balance between access to, and appropriate use of safe and effective antimicrobial medicines. In order to promote a global multisectoral approach to addressing the emergence and spread of antimicrobial

resistance, in May 2015 the World Health Assembly adopted a global action plan on AMR, which outlines five objectives to:

- improve awareness and understanding of AMR through effective communication, education and training;
- strengthen knowledge and the evidence base through surveillance and research;
- reduce the incidence of infection through effective sanitation, hygiene and infection prevention measures;
- optimize the use of antimicrobial medicines in human and animal health; and
- develop an economic case for sustainable investment that takes account of the needs of all countries and increase investment in new medicines and diagnostic tools.

To support the implementation of the global action plan to tackle the threat of AMR, WHO is supporting countries to develop, implement and monitor their national action plans on AMR through providing guidance, tools and technical assistance. This has resulted in 157 countries and territories establishing national action plans for AMR. In addition, close to 120 countries have now enrolled in WHO's Global Antimicrobial Resistance and Use Surveillance System (GLASS), the number of countries collecting and sharing data on AMR linked to the new SDG indicator (3.d.2) has tripled, and there has been a substantial increase in the number of samples collected and analysed globally.

To expedite the implementation of national action plans, greater political commitment and financing are urgently needed. In this regard, the Global Leaders Group on Antimicrobial Resistance and AMR Multi-Partner Trust Fund have been established, the latter of which is now supporting 10 countries to implement targeted One Health activities within their national action plan.

While AMR is a global challenge, it is clear that international refugee and migrant populations may be particularly vulnerable to rising AMR. The draft WHO global action plan for promoting the health of refugees and migrants,¹ adopted by the World Health Assembly in 2019, emphasizes the importance of appropriate

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_31733

